BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31981455)

  • 1. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
    Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
    Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
    Wang J; Hu C; Wang J; Shen Y; Bao Q; He F; Wang H; Gong L; Liu Z; Hu F; Liang J; Zhou Q; Wei L; Wen J; Zhang W
    J Immunother; 2019; 42(9):321-330. PubMed ID: 31219973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
    Wang J; Hu F; Yu P; Wang J; Liu Z; Bao Q; Zhang W; Wen J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5127-5138. PubMed ID: 36348018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
    Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
    J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
    Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
    J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-200a promotes proliferation and invasion of ovarian cancer cells by targeting PTEN.
    Jiang JH; Lv QY; Yi YX; Liao J; Wang XW; Zhang W
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6260-6267. PubMed ID: 30338796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
    Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
    Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
    Liu Z; Wen J; Hu F; Wang J; Hu C; Zhang W
    Cancer Sci; 2022 Feb; 113(2):432-445. PubMed ID: 34927311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
    World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection.
    Zheng X; Dong L; Wang K; Zou H; Zhao S; Wang Y; Wang G
    Ann Surg Oncol; 2019 Mar; 26(3):884-893. PubMed ID: 30565043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of Interleukin 21 Reduction in Osteosarcoma Patients Due to PD-1/PD-L1-Mediated Suppression of Follicular Helper T Cell Functionality.
    Gao W; Zhou J; Ji B
    DNA Cell Biol; 2017 Sep; 36(9):794-800. PubMed ID: 28650673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
    Oki E; Okano S; Saeki H; Umemoto Y; Teraishi K; Nakaji Y; Ando K; Zaitsu Y; Yamashita N; Sugiyama M; Nakashima Y; Ohgaki K; Oda Y; Maehara Y
    Oncology; 2017; 93(6):387-394. PubMed ID: 28910818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p.
    Zhou WY; Zhang MM; Liu C; Kang Y; Wang JO; Yang XH
    J Cell Physiol; 2019 Dec; 234(12):23176-23189. PubMed ID: 31206665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
    Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
    Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.